Title: Unveiling the autoreactome: Proteome-wide immunological fingerprints 1 reveal the promise of plasma cell depleting therapy 2

3

Authors: Aaron Bodansky¹, David JL Yu^{2*}, Alysa Rallistan^{3*}, Muge Kalaycioglu^{4*}, Jim

4 Boonyaratanakornkit^{5,6}, Damian J. Green^{5,6}, Jordan Gauthier^{5,6}, Cameron J. Turtle^{5,6**}, Kelsey 5

Zorn⁷, Brian O'Donovan⁷, Caleigh Mandel-Brehm⁷, James Asaki⁸, Hannah Kortbawi^{7,9}, Andrew 6

- F. Kung^{7,10}, Elze Rackaityte⁷, Chung-Yu Wang¹², Aditi Saxena¹², Kimberly de Dios², Gianvito 7
- Masi^{13,14}, Richard J. Nowak¹³, Kevin C. O'Connor^{13,14}, Hao Li⁷, Valentina E. Diaz¹⁵, Kaitlin B. 8
- Casaletto¹⁵, Eva Q. Gontrum¹⁵, Brandon Chan¹⁵, Joel H. Kramer¹⁵, Michael R. Wilson^{16,17}, Paul 9
- J. Utz³[†], Joshua A. Hill^{5,6}[†], Shaun W. Jackson^{18,19,20}[†], Mark S. Anderson²[†], Joseph L. 10
- DeRisi^{7,12}† 11
- 12
- 13 *: These authors contributed equally to this work.
- 14 †: These authors contributed equally to this work.
- 15

16 **Affiliations:**

- 17 ¹ Department of Pediatrics, Division of Critical Care, University of California San Francisco, 18 San Francisco, CA
- 19 ² Diabetes Center, School of Medicine, University of California San Francisco, San 20 Francisco, CA.
- ³ Department of Medicine, Division of Immunology and Rheumatology, Stanford University, 21 22 Stanford, CA 94305
- 23 ⁴ Institute of Immunity, Transplantation, and Infection (ITI), Stanford University, Stanford, CA 94305 24
- 25 ⁵ Fred Hutchinson Cancer Center, Seattle, WA, USA
- 26 ⁶ University of Washington School of Medicine, Seattle, WA, USA
- 27 ⁷ Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 28
- 29 ⁸ Biomedical Sciences Program, University of California San Francisco, San Francisco, CA.
- 30 ⁹Medical Scientist Training Program, University of California San Francisco, San Francisco, 31 CA.
- ¹⁰ Biological and Medical Informatics Program, University of California San Francisco, San 32 33 Francisco, CA
- ¹¹ Medical Scientist Training Program, University of California San Francisco, San 34
- Francisco, CA 35
- 36 ¹² Chan Zuckerberg Biohub SF, San Francisco, CA
- 37 ¹³ Department of Neurology, Yale School of Medicine, New Haven, CT
- ¹⁴ Department of Immunobiology, School of Medicine, Yale University, New Haven, CT 38

 ¹⁶ Weill Institute for Neurosciences, University of California San Francisco; San Francisco, CA ¹⁷ Department of Neurology, University of California San Francisco; San Francisco, CA ¹⁸ Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA ¹⁹ Seattle Children's Research Institute, Seattle, WA ²⁰ Pediatrics, University of Washington School of Medicine, Seattle, WA Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapics, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactivities" and that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases. 	39 40	¹⁵ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA
 ¹⁷ Department of Neurology, University of California San Francisco; San Francisco, CA ¹⁸ Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA ¹⁹ Seattle Children's Research Institute, Seattle, WA ²⁰ Pediatrics, University of Washington School of Medicine, Seattle, WA Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody mediated diseases. ⁶⁶⁶ ⁶⁷⁶ ⁶⁷⁶ ⁶⁷⁶ ⁶⁷⁷ ⁶⁷⁸ 	41 42	¹⁶ Weill Institute for Neurosciences, University of California San Francisco; San Francisco, CA
 ¹⁸Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA ¹⁹Seattle Children's Research Institute, Seattle, WA ²⁰Pediatrics, University of Washington School of Medicine, Seattle, WA Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that cach individual, regardless of disease state, possesses a distinct set of autoreactories constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody mediated diseases. ¹⁸profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases. 	43	¹⁷ Department of Neurology, University of California San Francisco; San Francisco, CA
 ¹⁹ Seattle Children's Research Institute, Seattle, WA ²⁰ Pediatries, University of Washington School of Medicine, Seattle, WA Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease ctiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repetiories. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases. 	44 45	¹⁸ Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA
²⁰ Pediatrics, University of Washington School of Medicine, Seattle, WA Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repertoires. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases.	46	¹⁹ Seattle Children's Research Institute, Seattle, WA
Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repertoires. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases. 66 77 78 79 70 71 72 73 74	47 48	²⁰ Pediatrics, University of Washington School of Medicine, Seattle, WA
/9	48 49 51 52 53 55 57 59 601 62 63 66 67 68 69 701 72 73 74 75 77 78 79	Abstract: The prevalence and burden of autoimmune and autoantibody mediated disease is increasing worldwide, yet most disease etiologies remain unclear. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leverage advances in programmable-phage immunoprecipitation (PhIP-Seq) methodology to explore the modulation, or lack thereof, of proteome-wide autoantibody profiles in both health and disease. We demonstrate that each individual, regardless of disease state, possesses a distinct set of autoreactivities constituting a unique immunological fingerprint, or "autoreactome", that is remarkably stable over years. In addition to uncovering important new biology, the autoreactome can be used to better evaluate the relative effectiveness of various therapies in altering autoantibody repertoires. We find that therapies targeting B-Cell Maturation Antigen (BCMA) profoundly alter an individual's autoreactome, while anti-CD19 and CD-20 therapies have minimal effects, strongly suggesting a rationale for BCMA or other plasma cell targeted therapies in autoantibody mediated diseases.

It is made available under a CC-BY-NC 4.0 International license .

80 **Main:**

81

82 Introduction:

83

Autoantibodies have been identified in a wide range of autoimmune diseases^{1–4}. In many cases 84 these autoantibodies are directly pathogenic ⁵⁻¹⁰, while in others they amplify or support T cell 85 driven pathologies^{6,11}. Numerous technologies now allow for the detection of autoantibodies to 86 many proteins simultaneously^{12–15}, and in the case of phage immunoprecipitation and sequencing 87 (PhIP-Seq), the entire human proteome¹⁶, using relatively small amounts of plasma or serum. 88 89 Using these new tools, a wide spectrum of novel autoantibodies have been discovered to be associated with various disease states^{11,17–21}, including, but not limited to, paraneoplastic 90 91 encephalitis, lipodystrophy, inborn genetic disorders, and multisystem inflammatory syndrome in 92 children (MIS-C)^{11,16–23}. To accurately identify shared autoreactive profiles among individuals 93 that also share a disease state, we and others have found that serum samples from large numbers 94 of healthy individuals are required, due to the presence of highly diverse autoreactivities present 95 in every individual¹⁷. However, it remains unclear whether individual autoreactive signatures are stable or variable with time or with immunosuppressive treatment. Here, we leveraged a custom 96 97 proteome-wide PhIP-Seq autoantibody discovery platform to comprehensively profile the 98 autoreactive repertoire in healthy individuals, and discovered that each individual harbors a 99 unique, distinctive, and highly reproducible set of autoreactivities we term the "autoreactome". 100 Using longitudinal samples from an additional cohort of healthy individuals, we determined that

an individuals' autoreactome, once formed, remains minimally changed over the course of years.

102

103 Extending these findings, we explored the impact of B cell depletion therapies upon the 104 autoreactome. Various surface markers are expressed and then downregulated over the course of B cell development and maturation^{24,25}. A subset of these surface markers are targeted by B cell 105 106 depleting therapies which are used to treat suspected autoantibody mediated diseases, yet a 107 comprehensive evaluation of the effects of these treatments on autoantibodies remains lacking. 108 The most commonly used agent, rituximab, targets CD20, which is not expressed by antibody 109 secreting cells²⁶. Recently, chimeric antigen receptor T cell (CAR-T) therapy targeting CD19 110 positive cells was shown to be safe and effective in the treatment of refractory systemic lupus erythematosus (SLE)²⁷. CD19 is expressed on naive and memory B cells, with reduced 111 expression on plasmablasts and plasma cells^{28,29}. CAR-T cells targeting B cell maturation 112 antigen (BCMA), which is expressed primarily by antibody secreting plasma cells^{30,31}, are 113

approved for the treatment of multiple myeloma^{32,33}. Here, we examined the impact of three

115 major B cell depleting therapies, rituximab (anti-CD20), anti-CD19 CAR-T cells, and anti-

116 BCMA CAR-T cells by PhIP-Seq and validate our findings using orthogonal assays. Our

117 findings demonstrate profound impact of anti-BCMA targeted therapies and minimal impact of

- 118 therapies targeting CD19 or CD20 on individuals' autoantibody signatures.
- 119

120 Healthy individuals harbor a unique set of autoreactivities: the "autoreactome"

121 The search for disease causing or associated autoantibodies is confounded by the fact that

autoreactive antibodies are present in all healthy individuals. We have previously shown that

123 large numbers of healthy samples are required to control for this natural confounder and avoid

124 false positive associations¹⁷. To better understand the variation of the autoreactive antibodies

between and within healthy individuals, we obtained serum from 79 pre-COVID healthy blood

It is made available under a CC-BY-NC 4.0 International license .

- 126 donors ("Healthy" demographics in Extended Data Table 1) and used our customized, previously
- described 768,000 element phage immunoprecipitation and sequencing platform(PhIP-Seq)^{11,17-}
- ^{21,34} to determine the proteome-wide set of autoreactivities present within each individual
- 129 (hereafter referred to as the "autoreactome").
- 130
- 131 To determine inter- and intra-individual similarity by PhIP-Seq requires high reproducibility as
- 132 measured by technical replicate. Over the past several years, we have refined our PhIP-Seq
- 133 protocols to maximize reproducibility. The master version of this protocol is available at:
- 134 <u>https://www.protocols.io/view/derisi-lab-phage-immunoprecipitation-sequencing-ph-</u>
- 135 <u>czw7x7hn?step=14.1</u>. PhIP-Seq protocol performance was evaluated by identifying the PhIP-Seq
- 136 enrichment similarity of 24 sets of technical duplicates using serum from healthy controls. The
- 137 raw signal (reads per 100k; rpk) of each phage-presented peptide which was immunoprecipitated
- 138 within a given sample was calculated, and then used to compare each individual sample.
- 139 Technical replicates showed high reproducibility (Pearson R-coefficient median =0.946; first
- 140 quartile (Q1) = 0.907, third quartile (Q3) = 0.974) (Fig. 1a: Left Panel).
- 141

142 Next, the similarity of individual autoreactomes was compared between each of the 79 healthy

- 143 individuals in this study. For each sample, the PhIP-Seq enrichment was compared to each of the
- 144 78 other samples. We found that individual autoreactomes were distinctive, with very little
- similarity to others (Pearson R-coefficient median = 0.021; Q1=0.018, Q3=0.023)(Fig. 1a: Right
- 146 Panel).
- 147

148 The autoreactome is longitudinally stable

149 While individual autoreactomes appear distinct, it remained an open question whether these

- 150 profiles were stable over time within a given individual. To address this question, we performed
- 151 PhIP-Seq on longitudinal serum samples from 7 distinct healthy individuals collected over a
- median of 63 months (35 samples total; Q1=55.5 months, Q3=76 months) ("Longitudinal"
- 153 demographics in Extended Data Table 1). None of these individuals were being treated with
- 154 immunomodulatory agents at any point during sample collection, however one had basal cell
- 155 carcinoma and another had a history of Sjögren's disease (clinical details in Extended Data Table
- 156 2). We compared the complete PhIP-Seq enrichment profile for each sample to all other samples.157 (Fig. 1b). These results clearly revealed that the intraindividual autoreactome profiles were
- highly correlated (Pearson R-coefficient median=0.883; Q1 =0.817, Q3=0.940). Conversely, the
- autoreactome of longitudinal samples within an individual was significantly more similar to each
- 160 other than to the autoreactomes between different individuals (Mann-Whitney U p-value=4.91e⁻
- ⁹⁵). Additionally, the distribution of intraindividual correlations overlapped considerably with the
- 162 distribution from technical replicates (104 of 146 (71.2%) longitudinal sample R-values fall
- 163 within 2 standard deviations of the mean of technical replicate R-values), indicating that in most
- 164 cases longitudinal autoreactomes are as similar to one another as technical replicates (Fig. 1c).
- 165 These results suggest that the dominant humoral determinants of autoreactivity within an
- 166 individual are not subject to large variation by this assay, at least within the median 5-year time
- 167 scale of this analysis.
- 168

169 Figure 1. Individuals harbor a unique set of longitudinally stable autoreactivities

It is made available under a CC-BY-NC 4.0 International license .



170

(a) Correlation matrices showing Pearson correlation coefficients of complete PhIP-Seq signal in
 healthy individuals. Left: 48 samples representing 24 individuals in technical replicate. Right: 79

distinct individuals. (b) Correlation matrix showing Pearson R-values of complete PhIP-Seq

174 signal in 7 distinct individuals each of whom have serial samples over at least 3 years. (c) Kernel

175 density estimate plot showing distribution of Pearson R correlation coefficients among technical

176 replicates, individuals over time, and between different individuals.

177

178 The autoreactome is driven by rare autoreactivities and minimally altered by IVIG

- 179 We and others have used PhIP-Seq to investigate autoimmune disease determinants; however,
- 180 many patients with immune disorders or deficiencies are treated with intravenous
- 181 immunoglobulin (IVIG). IVIG is pooled from thousands of donors³⁵ and therefore may contain
- relatively common autoantibodies, which has the potential to confound autoantibody assays³⁶. To

It is made available under a CC-BY-NC 4.0 International license .

183 investigate the effect of IVIG on intraindividual PhIP-Seq performance, we examined a cohort of

- 184 189 samples from patients with myasthenia gravis, an autoantibody-mediated autoimmune
- disease. Among these 189 samples we identified 4 paired sets of samples in which the first
- 186 collection was in a patient naïve to any immunomodulatory treatments, the second sample was
- 187 within 6 weeks of IVIG treatment (2 within days, 1 within 3 weeks, 1 within 6 weeks), and no
- additional immunomodulatory treatments had been given except for steroids and in one case
- azathioprine ("IVIG" demographics in Extended Data Table 1; sample details in Extended Data
- 190 Table 3).
- 191
- 192 PhIP-Seq was performed on these samples, and the mean correlation before and after IVIG was
- 193 0.815 (relative to 0.87 in longitudinal samples from individuals over time without any
- 194 intervention)(Extended Data Fig. 1a,b). To further determine whether there were directional
- 195 differences in the levels of PhIP-Seq detected autoantibodies following IVIG treatment, the sum
- 196 of the top 10 differentially enriched autoantibodies (see "Methods) derived from each individual
- 197 before and after IVIG administration was compared. No significant difference was observed
- 198 (two-sided paired-samples Wilcoxon test p-value=0.625) (Extended Data Fig. 1c) before and
- 199 after IVIG.
- 200

201 Rituximab treatment has minimal effect on the autoreactome

- 202 Depletion of CD20 positive B cells with rituximab is a common treatment in autoimmunity and
- 203 presumed autoantibody mediated diseases^{37–39}. To determine the extent to which rituximab
- treatment alters the autoreactome, we examined our cohort of 189 samples from patients with
- 205 myasthenia gravis to identify pairs of pre- and post-rituximab treatment samples. Like other
- autoantibody mediated diseases, treatment of myasthenia gravis can include multiple concurrent
- 207 therapies which could potentially alter the autoantibody profile of an individual. To be
- 208 conservative, we excluded all patients who had received any immunomodulation (including
- 209 IVIG and plasma exchange) other than rituximab, steroids, or azathioprine, and for whom a pre-
- treatment sample was not available. Using these stringent criteria, 35 longitudinal samples were
- identified from 7 individuals and analyzed by PhIP-Seq ("Rituximab" demographics in Extended
- 212 Data Table 1; sample clinical details in Extended Data Table 4).
- 213
- 214 The PhIP-Seq enrichment profile for each sample from a given individual who received
- rituximab was compared. Despite rituximab therapy, the autoreactome remained overall stable
- 216 within each individual over time (Pearson R-coefficient mean of 0.887; Q1=0.782,
- 217 Q3=0.940)(Fig. 2a). The overall distribution of correlation coefficients from individuals over
- time who received rituximab was similar to individuals who did not receive rituximab (108 of
- 219 136 (79.4%) within 2 standard deviations of the mean of R-values from longitudinal samples
- 220 without interventions) and was not significantly different (Mann-Whitney U test p-
- value=0.66)(Fig. 2b). While rituximab is known to transiently reduce certain antibodies, these
- results suggest the overall profile of autoreactivity post rituximab treatment remains essentially unchanged.
- 223 224
- 225 To determine whether there were decreases in subsets of PhIP-Seq enriched autoreactivities
- following rituximab treatment, as opposed to the complete profile, the sum of the top 10
- 227 differentially enriched protein targets (see "Methods") in each individual were calculated at the
- time of initial sample collection, and then tracked longitudinally following the first dose of

It is made available under a CC-BY-NC 4.0 International license .

- 229 rituximab. To avoid overlapping timelines, datapoints following an additional round of rituximab
- therapy were removed from this analysis. There was no significant difference in the overall
- autoreactivity at 1, 3, or 6 months post-rituximab therapy (one-way paired samples Wilcoxon test
- p-value=0.625 at 1 month, 0.125 at 3 months, and 0.3125 at 6 months) (Fig. 2c). While PhIP-Seq
- enrichment does not report on absolute immunoglobin levels, the levels of the disease-causing
- autoantibody (either anti-AChR or anti-MuSK antibodies) in myasthenia gravis were measured
 independently by a clinical radioimmunoassay (RIA; either Athena Diagnostic or Mayo Clinic
- Laboratory) in 6 of the 7 patients at the same timepoints. Although autoantibody levels
- minimally decreased in 3 patients, and moderately decreased in the other 3 patients following
- rituximab treatment, they never fell below the established positive cutoff for the assay (Extended
- 239 Data Fig. 2), suggesting that rituximab therapy was unable to quantitatively remove the
- 240 pathogenic autoantibodies.
- 241



242 Figure 2. Rituximab treatment does not significantly alter the autoreactome

243 244

(a) Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 7 distinct

individuals with myasthenia gravis each of whom were either rituximab naive or had not

- received rituximab for more than 6 months prior to first sample collection. Red arrows represent
- administration of rituximab. (b) Kernel density estimate plot showing distribution of Pearson R-
- 248 value correlation coefficients among longitudinal samples from individuals receiving rituximab
- relative to longitudinal samples from individuals received no intervention. (c) Lineplots showing
- the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) for each
- 251 patient over the first 6 months following initial rituximab dose. One-way paired samples
- 252 Wilcoxon test p-value=0.625 at 1 month, 0.125 at 3 months, and 0.3125 at 6 months.
- 253

254 CD19+ B cells are not required to maintain the autoreactome

- 255 To evaluate the impact of CD19 positive B cell depletion on the autoreactome, PhIP-Seq was
- 256 performed on samples prior to, and approximately 6-months following, anti-CD19 CAR-T
- therapy in 14 individuals being treated for lymphoma ("CD19 CAR-T" demographics in
- 258 Extended Data Table 1) who achieved and remained in remission, indicating successful depletion

259	of the targeted cells. In 13 of the 14 patients, circulating CD19 cells were either persistently
260	absent (defined as less than 10 CD19+ B cells per microliter) or became absent following
261	treatment. In the remaining patient, only a sample prior to therapy was available, and CD19 B
262	cells were already absent, indicating that they likely remained absent following additional
263	targeted CD19 depleting therapy (Extended Data Fig. 3). None of the individuals had received an
264	allogeneic hematopoietic cell transplant (HCT) in the preceding year (though two had received
265	an autologous HCT), and 12 of the 14 patients were free of any additional B cell depleting
266	therapies for the 6 months prior to initial sample collection. Intravenous immunoglobulin (IVIG)
267	is often administered to patients receiving B cell depleting therapy, and 5 of the 14 patients
268	received IVIG ("CD19" sample clinical details in Extended Data Table 5).
269	
270	The complete PhIP-Seq enrichment profile within each individual before and after CD19 CAR-T
271	therapy was once again compared. Despite depletion or persistently absent CD19 B cells in the
272	setting of active CD19 CAR-T therapy, the autoreactome remained remarkably stable over time
273	(Pearson R-coefficient median = 0.850 ; Q1= 0.770 , Q3= 0.921) (Fig. 3a).
274	
275	The overall distribution of correlation coefficients in the CD19 CAR-T therapy group was not
276	significantly different from intraindividual variation (Mann Whitney U p-value=0.284) The
277	distribution of correlation values in 12 of the 14 (85.7%) patients fell within the distribution (2
278	standard deviations from the mean) of longitudinal samples from healthy individuals who
279	received no interventions (Fig. 3b).
280	
281	Using the same analysis approach as described for rituximab, we assessed differential PhIP-Seq
282	enrichments using the sum of top 10 most enriched protein targets before and after CD19 CAR-1
283	treatment (see "Methods"). Of the 14 individuals evaluated, 11 had a decrease in enrichment
284	values while the remaining 3 had an increase, and levels overall were significantly decreased
285	(one-sided paired samples wilcoxon test p-value= 0.021) (Fig. 3c). However, the size of the
280	effect was minimal (median percent decrease in autoreactivity of 11.9%). These results suggest
28/	that similar to rituximab, sufficient immunoglobin producing cells remain after treatment such
200	that the pattern of autoreactivity by FIIF-Seq remains largery unancred.
209 200	Figure 3 CD10 CAP T therapy has minimal affect on the autoreactoms 6 months after
290 201	right 5. CD17 CAN-1 therapy has minimal effect on the autoreactome o months after trootmont
271	เป็นแม่น

It is made available under a CC-BY-NC 4.0 International license .



292 293 (a) Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 14 distinct 294 individuals before and after anti-CD19 CAR-T therapy. Yellow arrows represent the 6-month 295 post-treatment timepoint. (b) Kernel density estimate plot showing distribution of correlation 296 coefficients within each individual before and after therapy relative to the distribution among 297 untreated individuals over time and between different individuals. (c) Lineplots showing the 298 autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) for each 299 patient before and after treatment. One-sided paired samples Wilcoxon test p-value=0.021.

300

301 To orthogonally validate the PhIP-Seq results, serum from 9 of these 14 patients were assayed

302 using a previously described, multiplexed micro-bead assay consisting of 55 known protein

303 autoantigens, each of which was covalently bound to microbeads with distinct barcodes⁴⁰. The

304 list of autoantigens included proteins targeted in connective tissue diseases such as SLE,

It is made available under a CC-BY-NC 4.0 International license .

305 scleroderma, and myositis, as well as secreted proteins such as cytokines, chemokines and

- 306 growth factors. Additionally, antibody signal to 21 viral antigens was tested to determine
- 307 whether antibodies targeting both self-proteins and viral proteins respond similarly in the
- 308 absence of CD19+ B cells (see Extended Data Table 6 for a list of antigens). Because IVIG
- 309 contains autoantibodies that confound measurements in bead-based assays (our unpublished
- 310 observations), we excluded all patients who had received IVIG within 8 weeks of the initial
- 311 blood draw (pre CAR-T), or had received interim IVIG between the pre CAR-T and post CAR-T
- 312 (6 months after) blood draw. Nine of our 14 patients met these stringent criteria and were
- 313 included in these experiments.
- 314
- 315 As expected, a minority of autoantigens were recognized by serum IgG autoantibodies, including
- 316 3 intracellular proteins (thyroperoxidase, TPO; bactericidal permeability inducing protein, BPI;
- 317 and pyruvate dehydrogenase complex (PDC)) and 13 secreted proteins. Although levels of
- fourteen of these 16 autoantibodies had decreased signal overall (sum of normalized MFIs; see
- 319 "Methods") following anti-CD19 treatment, this decrease was only statistically significant in one
- 320 case (Extended Data Fig. 4a). Among the 17 antiviral antibodies with meaningful signal, 12 were
- 321 lower following CD19 therapy, but none were statistically significant (Extended Data Fig. 4b).
- 322 These data, generated with an orthogonal platform using full-length proteins as targets confirms
- 323 that the autoreactome, as well as IgG responses to viruses, remain largely stable over time
- 324 following anti-CD19 CAR-T therapy.
- 325

326 The autoreactome is profoundly altered following depletion of BCMA positive B cells

- 327 While CD19 is known to be expressed on a subset of antibody secreting plasma cells²⁹, BCMA is
- 328 a marker expressed on all plasma cells³¹, making it an attractive target for broad autoantibody
- depletion. To assess the impact of BCMA CAR-T on the autoreactome, we performed PhIP-Seq on serum samples from 9 individuals before, and approximately 6-months following, successful
- 330 on serum samples from 9 individuals before, and approximately 6-months following, successful 331 treatment with BCMA targeted CAR-T therapy ("BCMA" demographics in Extended Data Table
- 332 1). All 9 individuals had confirmed depletion of plasma cells in bone marrow following anti-
- 333 BCMA CAR-T treatment (Extended Data Fig. 5). Each individual was being treated for multiple
- myeloma, none had received a HCT in the previous year, and 6 of the 9 had not received any
- additional B cell depleting therapy in the provides year. All post-treatment samples were collected at
- least 56 days from the last dose of IVIG, and 3 of the 9 patients never received interim IVIG
- 337 ("BCMA" sample clinical details in Extended Data Table 5).
- 338

339 The complete PhIP-Seq enrichment profile obtained for each individual before and after anti-

340 BCMA CAR-T therapy was compared. In contrast to CD19 and CD20 targeting therapies, the

- 341 autoreactome was essentially devoid of any similarity following BCMA targeted therapy
- 342 (Pearson R-value median = 0.006; Q1=0.002, Q3=0.130) for 8 of the 9 individuals (Fig. 4a). The
- 343 autoreactome of one individual remained unaltered (R-value = 0.894). This individual was
- 344 subsequently found to have relapsed around the time of sample acquisition, indicating potential
- failure of the CAR-T treatment. The overall distribution of correlation coefficients in the BCMA
- 346 CAR-T therapy group was significantly different from alterations in healthy individuals over
- time without interventions (Mann Whitney U p-value=0.000012)(Fig. 4b). The samples from the
- individual with disease relapse were the only set whose autoreactome remained within 2 standard
- 349 deviations from the mean of individuals over time without treatment. Remarkably, of the
- remaining 8 individuals, 7 of them had autoreactome correlation values following anti-BCMA

- 351 CAR-T therapy that fell within 2 standard deviations of the mean of samples taken from entirely
- 352 different individuals. The observed complete "reset" of the autoreactome in these patients
- 353 suggest that successful treatment with anti-BCMA CAR-T cells sufficiently removes a lifetime
- of accumulated antibody producing plasma cells.
- 355
- 356 While the overall autoreactive profile in sera following anti-BCMA CAR-T treatment is
- 357 markedly altered, we also examined changes to the most differentially enriched protein targets
- 358 from pre-treatment samples. Patients with multiple myeloma have a monoclonal expansion of a
- 359 single plasma cell which secretes paraprotein antibody. Because paraprotein is potentially
- autoreactive, and because it is known to dramatically decrease following BCMA CAR-T
- treatment in multiple myeloma, we removed the top two enriched protein targets from each
- individual prior to analysis to minimize the chance that our results were being confounded by
- changes in paraprotein level. The autoreactivity levels for the top 3-12 proteins decreased in
 every patient follow anti-BCMA CAR-T therapy, and the overall change was statistically
- 365 significant (one-sided paired samples Wilcoxon test p-value=0.0019) (Fig. 4c and 4d). Unlike
- anti-CD19 CAR-T treatment, in which the size of the decrease was minimal, there was a 95.6
- 367 anti-CDT9 CAR-T treatment, in which the size of the decrease was infinitial, there was a 95.0 367 percent decrease in PhIP-Seq enrichment following anti-BCMA CAR-T treatment (Fig. 4e). To
- ensure these findings were similar if the top 10 protein targets were used (and potential
- 369 confounding by paraprotein is not accounted for), the same analysis was performed without the
- removal of the top 2 autoreactivities, with similar findings (Extended Data Fig. 6).
- 371
- 372 Figure 4. Anti-BCMA CAR-T therapy significantly alters the autoreactome

It is made available under a CC-BY-NC 4.0 International license .





(a) Correlation matrix showing Pearson R-values of complete PhIP-Seq signal in 9 distinct 375 individuals before and after anti-BCMA CAR-T therapy. Yellow arrows represent 6 month post-376 treatment time point. (b) Kernel density estimate plot showing distribution of correlation 377 coefficients within each individual before and after BCMA-targeted therapy relative to the 378 distribution among untreated individuals over time, and the distribution between different 379 individuals. (c) Heatmap showing top 10 autoreactivities (sum of top 10 PhIP-Seq Z-scores

380 relative to the 79 healthy controls) in each individual before and after treatment. (d) Lineplots

It is made available under a CC-BY-NC 4.0 International license .

381 showing the autoreactivity (sum of top 3 through 12 PhIP-Seq Z-scores relative to the 79 healthy

- 382 controls therefore accounting for potential paraprotein confounding) for each patient before and
- after treatment. One-sided paired samples Wilcoxon test p-value=0.0019. (e) Boxplots showing
- the relative distributions of autoreactivity before and after treatment with rituximab (sum of top
- 10), anti-CD19 CAR-T (sum of top 10), and anti-BCMA CAR-T (sum of top 3 through 12
- autoreactivities). Rituximab treatment cohort Mann-Whitney U p-value=0.42 with a median
- percent decrease of 52.3%; anti-CD19 CAR-T treatment cohort Mann-Whitney U p-value=0.206
- 388 with a median percent decrease of 11.9%; rituximab treatment cohort Mann-Whitney U p-
- 389 value=0.003 with a median percent decrease of 95.6%.
- 390
- 391 To orthogonally validate the PhIP-Seq results and further explore the effects of plasma cell
- depletion on antiviral antibodies, we used the same multiplexed bead-based arrays described
- 393 earlier to characterize IgG binding to 55 autoantigens and 21 viral proteins. However, because
- 394 IVIG is routinely given following BCMA CAR-T therapy, only 3 of the original 9 patients were
- 395 IVIG free, so samples from 4 additional patients meeting the stringent criteria outlined
- 396 previously were used (demographics and sample details in Extended Data Tables 7 and 8).
- 397
- 398 Of the same 16 measurable autoantigens analyzed in the anti-CD19 CAR-T treatment cohort, 13

399 had overall decreased IgG binding (sum of normalized MFIs; see "Methods") following anti-

400 BCMA CAR-T treatment. In contrast to the CD19 CAR-T cohort in which there was only one

- 401 autoantibody with a statistically significant decrease, levels of 9 of the 16 measured
- 402 autoantibodies significantly decreased following anti-BCMA CAR-T therapy (Extended Data
- 403 Figure 7a). Also, unlike the CD19 CAR-T cohort in which levels of none of the anti-viral
- 404 antibodies significantly decreased, all 17 of the measured antiviral antibodies decreased
- following BCMA therapy, and 8 of these decreases were statistically significant (Extended DataFigure 7b).
- 406 Figu: 407

408 **Discussion**

- 409 Adaptive immune responses targeting self rather than foreign proteins are a hallmark of
- 410 autoimmune disease. Previous work has noted the existence of circulating self-reactive
- 411 antibodies in healthy individuals. This work has focused on "natural autoantibodies", which are
- thought to arise without antigen stimulation and to consist primarily of unmutated, polyreactive,
- 413 often IgM-class antibodies^{41,42}. Despite considerable interest, the role of these antibodies in
- 414 health and disease remains unclear, though there is evidence of variable and context-dependent
- 415 roles; the autoantibodies can contribute to, or protect against, inflammatory and autoimmune
- 416 disease^{43–53}. The natural autoantibody repertoire is thought to be relatively shared amongst
- 417 individuals, and to develop during the first few years of life^{42,54–56}. Though natural
- 418 autoantibodies may target autoantigens present in autoimmune disease, substantial evidence
- 419 exists that the specific epitope differs from the disease-associated autoantibody, which may in
- 420 part explain why the healthy individuals studied here are clinically immune tolerant ^{57,58}.
- 421
- 422 Here, through the targeted application of a custom proteome-wide autoantibody detection
- 423 technology, we find that the repertoire of auto-reactive immunoglobins present in each healthy
- 424 individual is highly distinctive. This "autoreactome" is described by the complex set of
- thousands of peptides reproducibly enriched by immunoprecipitation, and apparently unique to
- 426 each individual. We observe that the autoreactome profile of individuals is remarkably stable,

It is made available under a CC-BY-NC 4.0 International license .

427 even over years of time, and thus may be considered a "serological fingerprint." In contrast to

- 428 natural autoantibodies, the autoreactome is characterized by uniqueness in each individual, rather
- 429 than a common, shared set of autoreactivities. Interestingly, the stability and uniqueness of the
- 430 autoreactome suggests that our approach may be utilized to de-convolute the origin of an
- 431 unknown patient serum sample in repositories where multiple samples have been collected at
- 432 different timepoints from the same patient.
- 433

434 During a humoral immune response, plasma cells of varied lifespans are generated, with short-435 lived plasmablasts providing rapid antibody production in the acute phase and long-lived plasma 436 cells sustaining durable antibody titers. While foreign antigen-specific long-lived plasma cells 437 are known to persist for decades in humans^{59–61}, the cellular phenotype of pathogenic plasma 438 cells remains controversial. Since individual autoantibodies decline following therapeutic B cell 439 ablation, despite a lack of CD19 and CD20 expression on plasma cells^{27,62,63}, the prevailing 440 model holds that the continuous generation of short-lived plasma cells from memory B cell 441 precursors underlies the autoantibody repertoire⁶⁴. In contrast with this view, we show that not 442 only is the broader intraindividual autoreactome stable over time, but that this autoantibody 443 repertoire is resistant to therapeutic B cell ablation with rituximab (anti-CD20) and anti-CD19 444 CAR-T cells. Given the expanded options for targeting B cells and plasma cells in systemic 445 autoimmunity, this enhanced understanding of autoreactome biology has important clinical 446 implications. Indeed, by using the autoreactome as a proxy for the autoantibody repertoire within 447 an individual, we show here that depletion of plasma cells via anti-BCMA CAR-T therapy 448 drastically alters the autoantibody repertoires. In most cases, the autoreactome of a sample after

- treatment with BCMA CAR-T cells appears as similar to an entirely different person as tothemselves prior to treatment.
- 451

452 It has been shown that rituximab reduces the level of certain autoantibodies⁶⁵, and has clinical 453 efficacy in many autoimmune disease settings, which may relate more to the antigen presentation

- 455 enhacy in many autominute disease settings, which may relate more to the antigen presentation
 454 function of CD20-positive B cells as proposed by others⁶⁶. Additionally, CD19 CAR-T therapy
- 455 has recently been shown to be effective in the treatment of refractory SLE. Because both anti-
- 456 CD19 CAR-T and anti-BCMA CAR-T are primarily used in the treatment of hematologic 457 malignancy, our cohorts received chemotherapy prior to CAR-T therapy, and therefore had low
- 458 CD19 and plasma cells numbers even prior to the initiation of therapy. Future studies will be
- 459 required to further understand the relationship of the pre- and post-CAR-T treatment
- 460 autoreactomes, and its relationship to clinical efficacy, in the specific context of autoimmune
- 461 diseases. Our broad based approach to screen autoantibodies at a proteome wide level allows a
- 462 more comprehensive and unbiased assessment of the effect of therapies on the specificity of the
- 463 autoreactome. We posit that this approach could greatly complement emerging data on the use of
- 464 CAR-T cell therapies that are being utilized against severe autoimmune diseases.
- 465
- 466 The prevalence and burden of autoimmune disease continues to rise^{67,68}, yet the precise
- 467 mechanisms for the development of autoreactivity remain unclear. There is mounting evidence
- that combinations of genetic and environmental risk factors, including viral infections,
- 469 predispose individuals to disease. In addition to the emerging therapies already discussed, other
- 470 new therapies exist which can halt or prevent the progression of certain autoimmune diseases,
- 471 including type 1 diabetes (T1DM)⁶⁹. By defining the autoreactome and describing the expected
- 472 longitudinal changes over time, we introduce a new tool which can be applied for additional

473 474 475 476 477 478 479 480 481 482 483	basic and translational studies in autoimmunity. Future work will be needed to explore the autoreactome to determine at what age it develops, whether there are shared features of autoreactive epitopes, what drives the development of the autoreactivities, and what biological role these autoreactive antibodies may have in health and disease. Beyond the already discussed application for evaluating the relative effectiveness of various emerging therapies, there are additional potential future applications of this work by tracking longitudinal autoreactome changes in individuals prior to, and following, the development of specific autoimmune diseases. This may allow for the identification of autoreactive signatures which precede the development of symptoms, and thereby produce novel biomarkers to identify patients in whom autoimmune disease could be prevented.					
484	Re	ferences				
485 486	1.	Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support				
487		diagnosis of myositis. J. Intern. Med. 280, 8-23 (2016).				
488	2.	Kawasaki, E. Anti-Islet Autoantibodies in Type 1 Diabetes. Int. J. Mol. Sci. 24, (2023).				
489	3.	Lou, H., Ling, G. S. & Cao, X. Autoantibodies in systemic lupus erythematosus: From				
490		immunopathology to therapeutic target. J. Autoimmun. 132, 102861 (2022).				
491	4.	Pihoker, C., Gilliam, L. K., Hampe, C. S. & Lernmark, A. Autoantibodies in diabetes.				
492		Diabetes 54 Suppl 2, S52-61 (2005).				
493	5.	Jarius, S. et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.				
494		<i>Brain</i> 131 , 3072–3080 (2008).				
495	6.	Dalmau, J. & Graus, F. Antibody-Mediated Encephalitis. N. Engl. J. Med. 378, 840-851				
496		(2018).				
497	7.	Marignier, R. et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease.				
498		Lancet Neurol. 20, 762–772 (2021).				
499	8.	Vincent, A. et al. Serological and experimental studies in different forms of myasthenia				
500		gravis. Ann. N. Y. Acad. Sci. 1413, 143-153 (2018).				
501	9.	Dalmau, J. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated				
502		with ovarian teratoma. Ann. Neurol. 61, 25–36 (2007).				

- 503 10. Fröhlich, E. & Wahl, R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in
- 504 Thyroid and Extra-Thyroidal Diseases. *Front. Immunol.* **8**, 521 (2017).
- 505 11. Bodansky, A. et al. A distinct cross-reactive autoimmune response in multisystem
- 506 inflammatory syndrome in children (MIS-C). *medRxiv* (2023)
- 507 doi:10.1101/2023.05.26.23290373.
- 508 12. Wen, X. et al. Identification of Novel Serological Autoantibodies in Takayasu Arteritis
- 509 Patients Using HuProt Arrays. *Mol. Cell. Proteomics* **20**, 100036 (2021).
- 510 13. Wang, E. Y. *et al.* High-throughput identification of autoantibodies that target the human
 511 exoproteome. *Cell Rep Methods* 2, (2022).
- 512 14. Chang, S. E. *et al.* New-onset IgG autoantibodies in hospitalized patients with COVID-19.
 513 *Nat. Commun.* 12, 5417 (2021).
- 514 15. Teymennet-Ramírez, K. V., Martínez-Morales, F. & Trejo-Hernández, M. R. Yeast Surface
- 515 Display System: Strategies for Improvement and Biotechnological Applications. *Front*
- 516 *Bioeng Biotechnol* **9**, 794742 (2021).
- 517 16. Larman, H. B. et al. Autoantigen discovery with a synthetic human peptidome. Nat.
- 518 Biotechnol. 29, 535–541 (2011).
- 519 17. Vazquez, S. E. *et al.* Autoantibody discovery across monogenic, acquired, and COVID-19520 associated autoimmunity with scalable PhIP-seq. *Elife* 11, (2022).
- 521 18. Mandel-Brehm, C. *et al.* Autoantibodies to Perilipin-1 Define a Subset of Acquired
 522 Generalized Lipodystrophy. *Diabetes* 72, 59–70 (2023).
- 523 19. O'Donovan, B. et al. High-resolution epitope mapping of anti-Hu and anti-Yo
- autoimmunity by programmable phage display. *Brain Commun* **2**, fcaa059 (2020).

- 525 20. Mandel-Brehm, C. et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated
- 526 Paraneoplastic Encephalitis. N. Engl. J. Med. **381**, 47–54 (2019).
- 527 21. Vazquez, S. E. et al. Identification of novel, clinically correlated autoantigens in the
- 528 monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq. *Elife* 9, (2020).
- 529 22. Larman, H. B. et al. PhIP-Seq characterization of autoantibodies from patients with multiple
- 530 sclerosis, type 1 diabetes and rheumatoid arthritis. J. Autoimmun. 43, 1–9 (2013).
- 531 23. Xu, G. J. et al. Systematic autoantigen analysis identifies a distinct subtype of scleroderma
- 532 with coincident cancer. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E7526–E7534 (2016).
- 533 24. Sanz, I. et al. Challenges and Opportunities for Consistent Classification of Human B Cell
- and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 535 25. Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The Maintenance of Memory Plasma
 536 Cells. *Front. Immunol.* 10, 721 (2019).
- 537 26. Pavlasova, G. & Mraz, M. The regulation and function of CD20: an "enigma" of B-cell
 538 biology and targeted therapy. *Haematologica* 105, 1494–1506 (2020).
- 539 27. Mackensen, A. *et al.* Anti-CD19 CAR T cell therapy for refractory systemic lupus
- 540 erythematosus. *Nat. Med.* **28**, 2124–2132 (2022).
- 541 28. Haas, K. M. & Tedder, T. F. Role of the CD19 and CD21/35 receptor complex in innate
 542 immunity, host defense and autoimmunity. *Adv. Exp. Med. Biol.* 560, 125–139 (2005).
- 543 29. Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma
 544 diagnosis and therapy. *Exp. Hematol. Oncol.* 1, 36 (2012).
- 545 30. Tai, Y.-T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma.
- 546 *Immunotherapy* 7, 1187–1199 (2015).

- 547 31. O'Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow
- 548 plasma cells. J. Exp. Med. 199, 91–98 (2004).
- 549 32. Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in
- 550 multiple myeloma. J. Clin. Invest. **129**, 2210–2221 (2019).
- 33. Brudno, J. N. et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation
- 552 Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed
- 553 Multiple Myeloma. J. Clin. Oncol. **36**, 2267–2280 (2018).
- 34. Bodansky, A. *et al.* Autoantigen profiling reveals a shared post-COVID signature in fully
- recovered and long COVID patients. *JCI Insight* **8**, (2023).
- 35. Barahona Afonso, A. F. & João, C. M. P. The Production Processes and Biological Effects
 of Intravenous Immunoglobulin. *Biomolecules* 6, 15 (2016).
- 558 36. Burbelo, P. D. et al. Autoantibodies detected in MIS-C patients due to administration of
- 559 intravenous immunoglobulin. *bioRxiv* (2021) doi:10.1101/2021.11.03.21265769.
- 37. Narayanaswami, P. *et al.* International Consensus Guidance for Management of Myasthenia
 Gravis: 2020 Update. *Neurology* 96, 114–122 (2021).
- 38. Hauser, S. L. *et al.* B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N. Engl. J. Med.* 358, 676–688 (2008).
- 564 39. Marinho, A. et al. Biological therapy in systemic lupus erythematosus, antiphospholipid
- 565 syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. *Front.*
- 566 *Immunol.* **14**, 1117699 (2023).
- 567 40. Ayoglu, B. et al. Characterising the autoantibody repertoire in systemic sclerosis following
- 568 myeloablative haematopoietic stem cell transplantation. Ann. Rheum. Dis. 82, 670–680
- 569 (2023).

- 41. Mannoor, K., Xu, Y. & Chen, C. Natural autoantibodies and associated B cells in immunity
 and autoimmunity. *Autoimmunity* 46, 138–147 (2013).
- 572 42. Lacroix-Desmazes, S. et al. Self-reactive antibodies (natural autoantibodies) in healthy
- 573 individuals. J. Immunol. Methods **216**, 117–137 (1998).
- 43. Mannoor, K., Matejuk, A., Xu, Y., Beardall, M. & Chen, C. Expression of natural
- 575 autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J.
- 576 *Immunol.* **188**, 3628–3638 (2012).
- 577 44. Cohen, I. R. & Cooke, A. Natural autoantibodies might prevent autoimmune disease.
- 578 *Immunol. Today* 7, 363–364 (1986).
- 579 45. Coutinho, A., Kazatchkine, M. D. & Avrameas, S. Natural autoantibodies. *Curr. Opin.*580 *Immunol.* 7, 812–818 (1995).
- 581 46. Holodick, N. E., Zeumer, L., Rothstein, T. L. & Morel, L. Expansion of B-1a Cells with
- 582 Germline Heavy Chain Sequence in Lupus Mice. *Front. Immunol.* 7, 108 (2016).
- 583 47. Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector and
 584 regulator. *Nat. Rev. Immunol.* 10, 778–786 (2010).
- 585 48. Grönwall, C., Vas, J. & Silverman, G. J. Protective Roles of Natural IgM Antibodies. *Front.*586 *Immunol.* 3, 66 (2012).
- 49. Vas, J., Grönwall, C. & Silverman, G. J. Fundamental roles of the innate-like repertoire of
 natural antibodies in immune homeostasis. *Front. Immunol.* 4, 4 (2013).
- 589 50. Grönwall, C. & Silverman, G. J. Natural IgM: beneficial autoantibodies for the control of
 inflammatory and autoimmune disease. *J. Clin. Immunol.* 34 Suppl 1, S12-21 (2014).
- 591 51. Lobo, P. I. Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies
- in Health and Disease. *Front. Immunol.* 7, 198 (2016).

- 593 52. Szinger, D. et al. Following Natural Autoantibodies: Further Immunoserological Evidence
- 594 Regarding Their Silent Plasticity and Engagement in Immune Activation. *Int. J. Mol. Sci.*
- **5**95 **24**, (2023).
- 596 53. Gál, S. et al. Natural and Pathological Autoantibodies Show Age-Related Changes in a
- 597 Spontaneous Autoimmune Mouse (NZB) Model. Int. J. Mol. Sci. 24, (2023).
- 598 54. Mouthon, L. *et al.* Analysis of the normal human IgG antibody repertoire. Evidence that
- 599 IgG autoantibodies of healthy adults recognize a limited and conserved set of protein
- 600 antigens in homologous tissues. J. Immunol. 154, 5769–5778 (1995).
- 601 55. Mouthon, L. et al. Invariance and restriction toward a limited set of self-antigens
- 602 characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of
 603 healthy adults. *Proc. Natl. Acad. Sci. U. S. A.* 92, 3839–3843 (1995).
- 604 56. Mouthon, L. et al. The self-reactive antibody repertoire of normal human serum IgM is
- acquired in early childhood and remains conserved throughout life. *Scand. J. Immunol.* 44,
 243–251 (1996).
- 607 57. Piechaczyk, M. et al. Antigenic domains on the human thyroglobulin molecule recognized
- by autoantibodies in patients' sera and by natural autoantibodies isolated from the sera of
 healthy subjects. *Clin. Immunol. Immunopathol.* 45, 114–121 (1987).
- 610 58. Ronda, N. et al. Analysis of natural and disease-associated autoantibody repertoires: anti-
- 611 endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients
- 612 with systemic lupus erythematosus. *Int. Immunol.* **6**, 1651–1660 (1994).
- 613 59. Halliley, J. L. et al. Long-Lived Plasma Cells Are Contained within the CD19(-
- 614)CD38(hi)CD138(+) Subset in Human Bone Marrow. *Immunity* **43**, 132–145 (2015).

- 615 60. Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in
- 616 individuals responding to CD19-directed CAR T-cell therapy. *Blood* **128**, 360–370 (2016).
- 617 61. Hill, J. A. et al. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-
- 618 cell therapy. Am. J. Transplant 23, 416–422 (2023).
- 619 62. Joly, P. et al. First-line rituximab combined with short-term prednisone versus prednisone
- 620 alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group,
- 621 open-label randomised trial. *Lancet* **389**, 2031–2040 (2017).
- 622 63. Fervenza, F. C. et al. Rituximab or Cyclosporine in the Treatment of Membranous
- 623 Nephropathy. N. Engl. J. Med. **381**, 36–46 (2019).
- 624 64. Hale, M., Rawlings, D. J. & Jackson, S. W. The long and the short of it: insights into the
- 625 cellular source of autoantibodies as revealed by B cell depletion therapy. *Curr. Opin.*
- 626 *Immunol.* **55**, 81–88 (2018).
- 627 65. Díaz-Manera, J. *et al.* Long-lasting treatment effect of rituximab in MuSK myasthenia.
 628 *Neurology* 78, 189–193 (2012).
- 629 66. Hofmann, K., Clauder, A.-K. & Manz, R. A. Targeting B Cells and Plasma Cells in
- 630 Autoimmune Diseases. *Front. Immunol.* 9, 835 (2018).
- 631 67. Dinse, G. E. *et al.* Increasing Prevalence of Antinuclear Antibodies in the United States.
 632 *Arthritis Rheumatol* 74, 2032–2041 (2022).
- 633 68. Miller, F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an
- 634 urgent call to action for improved understanding, diagnosis, treatment, and prevention.
- 635 *Curr. Opin. Immunol.* **80**, 102266 (2023).
- 636 69. Waibel, M. *et al.* Baricitinib and β -Cell Function in Patients with New-Onset Type 1
- 637 Diabetes. N. Engl. J. Med. **389**, 2140–2150 (2023).

It is made available under a CC-BY-NC 4.0 International license .

638 Methods

639 Patients

640 The "Healthy Control" cohort consists of plasma from 79 self-reported healthy, pre-COVID-19

- 641 individuals which were obtained as deidentified samples from the New York Blood Center.
- 642 These samples were part of retention tubes collected at the time of blood donations from
- 643 volunteer donors who provided informed consent for their samples to be used for research.
- 644
- 645 For the bead-based protein arrays, serum and/or plasma was used for internal controls and
- 646 validations, as has been previously described, as deidentified samples⁷⁰. Negative controls
- 647 included a pediatric sample from an infant between 6 and 12 months of age which was a gift
- 648 from the Pulendran lab, as well as samples from 3 healthy subjects with known CMV-
- 649 seronegative status confirmed by ELISA from the Stanford Blood Center. Positive controls
- 650 include plasma samples derived from participants with autoimmune or other types of diseases
- 651 with known reactivity patterns (e.g. thyroid peroxidase [TPO], pyruvate dehydrogenase complex
- 652 [PDC-E2], fibroblast growth factor 7 [FGF7], proteinase 3, IL-11, CXCL-13) which were
- 653 purchased from ImmunoVision or were obtained from Stanford Autoimmune Diseases Biobank
- and Oklahoma Medical Research Foundation (Oklahoma City, Oklahoma, USA; a gift of Judith
- James, Oklahoma Medical Research Foundation). A total of 12 positive control patient samples
- 656 were used. All 16 of these patients (4 negative controls and 12 positive controls) provided 657 informed consent for their samples to be used for research.
- 658
- 659 Longitudinal plasma samples were obtained from a set of 7 community dwelling, cognitively
- 660 unimpaired, pre-COVID-19, healthy older adults recruited through the Brain Aging Network for
- 661 Cognitive Health (BrANCH) at the University of California, San Francisco. All participants are
- screened at baseline and enrollment criteria excluded individuals with severe psychiatric illness,
- 663 neurologic disorders (e.g., epilepsy, multiple sclerosis), and medical conditions that could impact
- 664 cognition (e.g., recent substance use disorders, active chemotherapy). Following a
- 665 comprehensive neurobehavioral evaluation, participants were classified cognitively normal per
- 666 consensus conference with board-certified neurologists and neuropsychologists. Inclusion in the
- 667 current study was contingent on no known autoimmune conditions at baseline or follow up visits, 668 either active or inactive at the time of plasma collection. Study procedures were approved by the
- 669 UCSF Committee on Human Research and all participants provided written informed consent
- 670 (IRB #10-02076).
- 671
- 672 For the myasthenia gravis patient cohort (used to evaluate the effects of IVIG and rituximab),
- 673 deidentified serum samples from myasthenia gravis patients, with laboratory confirmed AChR or
- 674 MuSK autoantibody serostatus, were retrieved from a biorepository established at the Yale
- 675 School of Medicine, Myasthenia Gravis Clinic (EXPLORE-MG Registry, NCT03792659) under
- 676 the approval of Yale University's Institutional Review Board.
- 677
- 678 The CAR-T cell cohorts consisted of adults aged ≥ 18 years with relapsed or refractory CD19+ or
- 679 BCMA+ hematologic malignancies who received lymphodepleting chemotherapy with
- 680 cyclophosphamide and fludarabine followed by anti-CD19 or anti-BCMA-CAR-T cells at Fred
- 681 Hutchinson Cancer Center (Fred Hutch). Serum and PBMCs were prospectively collected once

It is made available under a CC-BY-NC 4.0 International license .

- prior to lymphodepleting chemotherapy and at approximately 6-12 months after CAR-T cell 682
- 683 infusion among individuals who achieved durable remissions and received no subsequent anti-
- 684 tumor therapies. This work was approved by the Fred Hutch institutional review board (Protocol
- 685 10080), and all participants provided informed consent in accordance with the Declaration of 686 Helsinki.
- 687

688 **PhIP-Seq**

- 689 All PhIP-Seq was performed similar to our previously published multichannel protocol, with 690 minor adjustments as outlined in our new protocol; https://www.protocols.jo/yiew/derisi-lab-
- 691 phage-immunoprecipitation-sequencing-ph-czw7x7hn?step=14.1
- 692
- 693 As previously described¹¹, our human peptidome library consists of a custom-designed phage
- 694 library of 731,724 unique T7 bacteriophage each presenting a different 49 amino-acid peptide on
- 695 its surface. Collectively these peptides tile the entire human proteome including all known
- 696 isoforms (as of 2016) with 25 amino-acid overlaps. 1 milliliter of phage library was incubated
- 697 with 1 microliter of human serum overnight at 4C and immunoprecipitated with 25 microliters of
- 698 1:1 mixed protein A and protein G magnetic beads (Thermo Fisher, Waltham, MA, #10008D and
- 699 #10009D). These beads were than washed, and the remaining phage-antibody complexes were
- 700 eluted in 1 milliliter of E.Coli (BLT5403, EMD Millipore, Burlington, MA) at 0.5-0.7 OD and
- 701 amplified by growing in 37C incubator. This new phage library was then re-incubated with the
- 702 same individual's serum and the previously described protocol repeated. DNA was then
- 703 extracted from the final phage-library, barcoded, and PCR-amplified and Illumina adaptors 704
- added. Next-Generation Sequencing was then performed using an Illumina sequencer (Illumina,
- 705 San Diego, CA) to a read depth of approximately 1 million per sample. 706

707 **Bead-based protein array**

- 708 A 76-plex protein array comprising a 55-plex autoantigen protein subarray and a 21-plex viral 709 protein subarray was constructed as previously described, with modifications⁴⁰. In brief, antigens 710 (Extended Data Table 6) were conjugated to uniquely barcoded carboxylated magnetic beads 711 (MagPlex-C, Luminex Corp). The beads were stored in aliquots at -80°C after conjugation and 712 that the day of the experiment. 45 μ l of diluted serum or plasma sample (1:100 in PBS-713 1%BSA) was transferred into the 384-well plate (Greiner BioOne) containing 5 µl of bead array 714 per well. Samples were incubated for 60 min on a shaker at room temperature, and then at 4C 715 overnight. The following day beads were washed with 4×60 ul PBS-Tween on a plate washer
- 716 (EL406, Biotek) and then incubated with 50 µl of 1:1000 diluted R-phycoerythrin (R-PE)
- 717 conjugated Fc-y-specific goat anti-human IgG F(ab')2 fragment (Jackson ImmunoResearch 109-
- 718 116-170) for 30 min. The plate was washed with $4 \times 60 \,\mu$ l PBS-Tween and re-suspended in 50
- 719 ul PBS-Tween prior to analysis using a FlexMap3D TM instrument (Luminex Corp.) and
- 720 measuring MFI with at least 50 beads per barcode for each sample. Most of the individual
- 721 antigens that had been conjugated to beads were qualified prior to mixing using antibodies-722
- directed against epitope tags, monoclonal antibodies specific for the antigen, or prototype human 723 plasma samples derived from participants with autoimmune diseases with known reactivity
- 724 patterns (e.g., Scl-70+ systemic sclerosis; SSA+, which is associated with lupus and Sjögren's
- 725 syndrome; ribonucleoprotein (RNP)+ sera, which is associated with lupus and mixed connective
- 726 tissue disease; and APS1 sera which are reactive with multiple cytokines; data not shown).

It is made available under a CC-BY-NC 4.0 International license .

- 727 Binding events were displayed as Median Fluorescence Intensity (MFI). MFI values were
- normalized by subtracting bare-bead MFI values. Replicate MFI values were averaged.
- 729

730 Enumeration of B cells and plasma cells

- 731 B cells were quantified using a research flow cytometry panel (Representative gates shown in
- 732 Extended Data Fig. 8). Briefly, peripheral blood mononuclear cells (PBMCs) were incubated on
- ice for 30 minutes with fluorescently labeled antibodies (in fluorescence-activated single cell
- sorting [FACS] buffer containing Dulbecco's phosphate-buffered saline [DPBS] and
- 1% newborn calf serum [Life Technologies]) before its analysis on a FACSymphony A5 (BD
- 736 Bioscience) flow cytometer. The following antibodies were included for cell labeling: fixable
- 737 viability stain 700 (BD cat#564997), anti-CD19 BV421 (HIB19, BD), anti-CD45 BV510 (HI30,
- BD), anti-CD3 BV605 (UCHT1, BioLegend), anti-CD16 BV711 (3G8, BD), anti-CD14 BV711
- (M0P-9, BD). FlowJoTM Software version 10.7.1 was used for analyses with flow cytometry
- 740 proportions multiplied by absolute lymphocyte counts to calculate total $CD19^+$ B cell numbers.
- Plasma cells in the bone marrow were quantified based on detection of CD138⁺ plasma cells in
- clinically obtained bone marrow core biopsies by immunohistochemistry in the University of
- 743 Washington Hematopathology Laboratory.
- 744

745 Analysis of PhIP-Seq

- As previously described¹¹, next generation sequencing reads from fastq files were aligned at the
- 747 level of amino acids using RAPSearch2. All results represent the average of technical replicates,
- except for the 79 individual healthy controls in whom only 24 of the individuals (48 samples)
- 749 were performed in technical replicate. All human peptidome analysis was performed at the gene-
- reads for all peptides mapping to the same gene were summed, and 0.5 reads
- 751 were added to each gene to allow inclusion of genes with zero reads in mathematical analyses.
- 752 Within each individual sample, reads were normalized by converting to the percentage of total
- reads. To normalize each sample against background non-specific binding, a fold-change (FC)
 over mock-IP was calculated by dividing the sample read percentage for each gene by the mean
- read-percentage of the same gene for the AG bead only controls. This FC signal was then used
- for side-by-side comparison between samples and cohorts. FC values were also used to calculate
- 757 z-scores for specific cohorts relative to defined controls.
- 758

759 Analysis of multiplexed bead arrays

- Antibody reactivity to each target for each sample was measured in mean fluorescent intensity
- (MFI). Data is only shown for targets which have an MFI of at least 1000 MFI units at any time
- point for any patient. To adjust for background binding to beads only, each sample was
- additionally run on unconjugated beads, and bare bead MFI was subtracted to create an adjusted
- 764 MFI for each target antigen within the same corresponding sample. To account for nonspecific
- binding from human serum, a sample from an infant control known to lack antibodies to any of
- the viral or human targets was run in duplicate. The mean of the adjusted MFI's for the control
- duplicates was calculated for each target, and further subtracted from each corresponding target
- from each sample. A normalization function was then performed such that all sample values for
- reach target antigen ranged from zero to one, referred to as "Normalized MFI".
- 770
- 771 Statistical methods

It is made available under a CC-BY-NC 4.0 International license .

- All statistical analysis was performed in Python using the Scipy Stats package. To calculate the
- overall similarity of PhIP-Seq detected autoreactive profiles between different samples, a
- Pearson correlation coefficient was calculated using all FC over mock-IP values (unless
- specifically stated otherwise) for each autoantigen in each sample relative to each autoantigen in
- each other sample. For comparisons of distributions of PhIP-Seq signal (either autoreactivity
- scores or Pearson R-values) between two groups, a non-parametric Mann-Whitney U test was
 utilized. To determine whether specific interventions (IVIG, rituximab, anti-CD19 CAR-T, or
- anti-BCMA CAR-T) directionally decreased PhIP-Seq detected autoreactivities, first an
- 780 "autoreactivity" score was calculated by summing the top 10 autoantigen z-scores (relative to the
- 781 79 healthy controls) in each pre-treatment sample. The sum of the z-scores from these same 10
- autoantigens were again calculated following the intervention for each post-treatment sample
- from the same individual. These autoreactivity scores from before and after a treatment were
- paired within each individual, and used as input for a one-sided paired-samples Wilcoxon test.
- 785 To determine whether anti-CD19 CAR-T treatment, or anti-BCMA CAR-T treatment altered
- Luminex detected antibody levels from the bead-based protein arrays, the pre-treatment and
- 787 post-treatment normalized MFI values were compared using a two-sided paired-samples
- 788 Wilcoxon test for each target antigen. P-values: ns > 0.05, * < 0.05, ** < 0.01, *** < 0.005, **** 789 < 0.001.
- 790

791 Data Availability

- All PhIP-Seq data will be made publicly available upon publication of this manuscript via a
- 793 Dryad digital repository; DOI: 10.5061/dryad.w3r2280z6
- 794

795 Methods References

796 70. P. Cheung, F. Vallania, H. C. Warsinske, M. Donato, S. Schaffert, S. E. Chang, M. Dvorak,

- 797 C. L. Dekker, M. M. Davis, P. J. Utz, P. Khatri, A. J. Kuo, Single-Cell Chromatin Modification
- Profiling Reveals Increased Epigenetic Variations with Aging. *Cell.* **173**, 1385-1397.e14 (2018).
- 799

800 Acknowledgements

801 The authors acknowledge the New York Blood Center for contributing pre-COVID-19 healthy

- donor blood samples. We acknowledge Brian O'Donovan for coining the term "autoreactome".
- 803 The authors would like to thank Quinton R. Markett for assistance with organizing protein array 804 reagents and design.
- 805

806 Author Contributions

- 807 Conceptualization: A.B., H.L., M.R.W., J.A.H., S.W.J., M.S.A., J.L.D. Methodology: A.B., J.A.,
- A.F.K., H.K., E.R., C.Y.W., A.S., P.J.U., A.R., M.K., M.S.A., J.L.D. Performed or contributed to experiments: A.B., D.J.L.Y., A.R., M.K., J.B., C.M.B., B.O. Formal analysis: A.B., J.L.D.
- to experiments: A.B., D.J.L.Y., A.R., M.K., J.B., C.M.B., B.O. Formal analysis: A.B., J.L.D.
 Patient sample and clinical data acquisition: K.Z., K.D.D., V.E.D., E.Q.G., B.C., D.J.G, J.G.,
- Patient sample and clinical data acquisition: K.Z., K.D.D., V.E.D., E.Q.G., B.C., D.J.G, J.G.,
 C.J.T., J.A.H., G.M., R.J.W, K.C.O. Clinical data curation: K.Z., K.D.D., K.B.C., J.H.K.,
- V.E.D., E.Q.G., B.C., D.J.G, J.G., C.J.T., J.A.H., G.M, K.C.O. Writing (original draft): A.B.,
- V.E.D., E.Q.G., B.C., D.J.G. J.G., C.J.I., J.A.H., G.M., K.C.O. Writing (original draft): A.B.
- 813 J.L.D. Writing (review and editing): A.B., K.C.O., P.J.U., J.A.H, S.W.J., M.S.A., J.L.D.
- 814 Supervision: P.J.U., J.A.H, S.W.J., M.S.A., J.L.D.
- 815

816 Competing Interest Declaration

817

It is made available under a CC-BY-NC 4.0 International license .

818 Funding

- 819 This work was supported by the Pediatric Scientist Development Program and the Eunice
- 820 Kennedy Shriver National Institute of Child Health and Human Development grant K12-
- HD000850 (A.B.), and by the Chan Zuckerberg Biohub SF (J.L.D. and M.S.A.), and by National
- 822 Institutes of Health grants R01AR073938 and R01AR075813 (S.W.J) and by and the National
- 823 Cancer Institute (U01CA247548 to J.A.H.) and by the National Institute of Allergy and
- 824 Infectious Diseases of the NIH under award numbers R01-AI114780(K.C.O), R21-
- AI142198(K.C.O), R21 AI164590 (K.C.O) and through an awards provided through award
- 826 number U54-NS115054 (K.C.O) and NIH U54 NS115054 (G.M and R.J.N; G.M is also an
- 827 MGNet Scholar Awardee) of the Rare Diseases Clinical Research Network Consortium
- 828 (RDCRN) of the NIH and MGNet. All RDCRN consortia are supported by the network's Data
- 829 Management and Coordinating Center (DMCC) (U2CTR002818). This study was supported by
- NIH-NIA grants R01AG032289 (J.H.K) and R01AG072475(K.B.C), UCSF ADRC
- 831 P30AG062422 (G.D.R), This work was also supported by a grant from the Larry L. Hillblom
- Foundation (2018-A-006-NET; J.H.K). This work was also supported by the Henry Gustav
- 833 Floren Trust, the Stanford Department of Medicine Team Science Program, and funding from
- the Stanford Medicine Office of the Dean (P.J.U.).
- 835

836 **Potential Conflicts**

- 837 J.D.R. reports being a founder and paid consultant for Delve Bio, Inc., and a paid consultant for
- the Public Health Company and Allen & Co. M.A.S. receives unrelated research funding from
- the NIH, the CDC, Cepheid and Merck and unrelated Honoria from UpToDate, Inc. M.R.W.
- reports being a founder and paid consultant for Delve Bio, Inc. and receives unrelated research
- grant funding from Roche/Genentech and Novartis, and received speaking honoraria from
- Genentech, Takeda, WebMD, and Novartis. C.J.T. reports being on the Scientific Advisory
 Boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo
- Therapeutics, Celgene/BMS Cell Therapy; is a member a DSMB member of Kyverna; is on Ad
- hoc advisory boards/consulting (last 12 months) for Nektar Therapeutics, Legend Biotech,
- 846 Prescient Therapeutics, Century Therapeutics, IGM Biosciences, Abbvie; has Stock options in
- 847 Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, ArsenalBio, Cargo
- 848 Therapeutics; and reports the right to receive payment from Fred Hutch as an inventor on patents
- 849 related to CAR T-cell therapy. J.A.H. reports research funding from Merck and Takeda and
- 850 consulting fees from Takeda, Gilead, SentiBio, and Century Therapeutics. J.G. reports research
- funding from Sobi, Juno Therapeutics (a BMS company), Celgene (a BMS company),
- 852 Angiocrine Bioscience; is an Ad hoc consultant for Sobi, Legend Biotech, Janssen, Kite Pharma,
- 853 MorphoSys. D.J.G. has received research funding, has served as an advisor and has received
- 854 royalties from Juno Therapeutics, a Bristol-Myers Squibb company; has served as an advisor and
- 855 received research funding from Seattle Genetics; has served as an advisor for GlaxoSmithKline,
- 856 Celgene, Janssen Biotech, Ensoma and Legend Biotech; and has received research funding from
- 857 SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. K.C.O. received unrelated
 858 research funding from, and is an equity shareholder of Cabaletta Bio, and receives unrelated
- research funding from Seismic, argenx, and Viela Bio/Horizon (now Amgen). R.J.N. reports
- 860 unrelated research support from the National Institutes of Health, Genentech, Inc., Alexion
- 861 Pharmaceuticals, Inc., argenx, Annexon Biosciences, Inc., Ra Pharmaceuticals, Inc. (now UCB
- 862 S.A.), the Myasthenia Gravis Foundation of America, Inc., Momenta Pharmaceuticals, Inc. (now
- Janssen), Immunovant, Inc., Grifols, S.A., and Viela Bio, Inc. (now Horizon Therapeutics plc).

It is made available under a CC-BY-NC 4.0 International license .

- 864 R.J.N. has also served as a consultant/advisor unrelated to research in this manuscript for
- 865 Alexion Pharmaceuticals, Inc., argenx, Cabaletta Bio, Inc., Cour Pharmaceuticals, CSL Behring,
- Grifols, S.A., Ra Pharmaceuticals, Inc. (now UCB S.A.), Immunovant, Inc., Momenta 866
- 867 Pharmaceuticals, Inc. (now Janssen), and Viela Bio, Inc. (now Horizon Therapeutics plc). J.L.D.,
- C.M.B. and M.R.W. receive licensing fees from CDI Labs. 868
- 869

870 Correspondence and requests for materials should be addressed to Mark S. Anderson 871 (mark.anderson@ucsf.edu) and Joseph L. DeRisi (joe@derisilab.ucsf.edu).

872

Extended Data Figures and Tables 873

874

875 Extended Data Figure 1. Administration of IVIG minimally alters the autoreactome



876

877 (a) Correlation matrices showing Pearson correlation coefficients of complete PhIP-Seq signal 878 before and after IVIG administration. (b) Kernel density estimate plot showing distribution of

Pearson R correlation coefficients from before and after IVIG administration relative to 879

- 880 longitudinal samples from individuals over time, and between different individuals. (c) Lineplots 881
- showing the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls)

882 for each patient before and after IVIG administration. Paired-samples Wilcoxon test p-value 0.625.

883 884

885 Extended Data Figure 2. Changes in disease-causing autoantibody levels following 886 rituximab



It is made available under a CC-BY-NC 4.0 International license .

888

889 Left: Anti-AChR autoantibody levels measured by radioimmunoassay (RIA; Mayo Clinic

890 Laboratory, unit=nmol/L) in 2 patients at 1 month, 3 months, and 6 months post-rituximab. RIA

- 891 positive cutoff 0.02 nmol/L. **Right**: Anti-MuSK autoantibody titers measured by RIA (Athenia
- B92 Diagnostics, unit=fold dilution) in a different 4 patients at 1 month, 3 months, and 6 months
- 893 post-rituximab. Positive cutoff for is a fold dilution of greater than 1:20.
- 894

895 Extended Data Figure 3: CD19 cell counts following anti-CD19 CAR-T treatment

896



897

898 Lineplots showing the levels of CD19⁺ B cells in peripheral blood measured by flow cytometry

at various timepoints relative to anti-CD19 CAR-T treatment, in each patient.

900

901 Extended Data Figure 4: Changes in multiplex bead-based protein array detected antibody

902 levels following CD19 therapy

It is made available under a CC-BY-NC 4.0 International license .



903

(a) Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each of the 16 autoantigens with meaningful signal (see "Methods") in each of the patients before and approximately 6 months after treatment with anti-CD19 CAR-T cells. P-values shown are from a paired-samples Wilcoxon test. (b) Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each of the 17 viral antigens with meaningful signal (see "Methods") in each of the patients before and after treatment with anti-CD19 CAR-T cells. P-values shown are from a re from a paired-samples Wilcoxon test.

- 911
- 912

913 Extended Data Figure 5: Changes in bone marrow plasma cell percentage following anti-

914 BCMA CAR-T cell therapy



- 915 Days Relative to CAR-1 Treatment 916 Lineplots showing the levels of plasma cells in the bone marrow measured by flow cytometry at
- 917 various timepoints relative to anti-BCMA CAR-T treatment, in each patient.
- 918

919 Extended Data Figure 6: Changes in PhIP-Seq detected autoreactivities following anti-





It is made available under a CC-BY-NC 4.0 International license .

- 922 (a) Lineplots showing the autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79
- healthy controls) for each patient before and after treatment. One-sided paired samples Wilcoxon
- test p-value=0.049. (b) Swarmplots showing the relative distributions of autoreactivity (sum of
- top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) before and after treatment with anti-
- 926 BCMA CAR-T. Mann-Whitney U p-value=0.006. (c) Boxplots showing the relative distributions
- 927 of autoreactivity (sum of top 10 PhIP-Seq Z-scores relative to the 79 healthy controls) before and
- 928 after treatment with rituximab, anti-CD19 CAR-T, and anti-BCMA CAR-T. rituximab treatment
- 929 cohort Mann-Whitney U p-value=0.42 with a median percent decrease of 52.3%; anti-CD19
- 930 CAR-T treatment cohort Mann-Whitney U p-value=0.206 with a median percent decrease of
- 11.9%; anti-BCMA CAR-T treatment cohort Mann-Whitney U p-value=0.006 with a median
- 932 percent decrease of 97.2%.
- 933

Extended Data Figure 7: Changes in multiplex bead-based protein array detected antibody levels following BCMA therapy



936

937 (a) Multiplex bead-based protein array detected normalized MFI values (see "Methods") for each938 of the 16 autoantigens with meaningful signal (see "Methods") in each of the patients before and

after treatment with anti-BCMA CAR-T cells. P-values shown are from a paired-samples

940 Wilcoxon test. (b) Multiplex bead-based protein array detected normalized MFI values (see

941 "Methods") for each of the 17 viral antigens with meaningful signal (see "Methods") in each of

It is made available under a CC-BY-NC 4.0 International license .

- 942 the patients before and after treatment with anti-BCMA CAR-T cells. P-values shown are from a
- 943 paired-samples Wilcoxon test.
- 944

945 Extended Data Figure 8: Flow cytometry gating strategy for identification of CD19⁺ B cells



Representative flow cytometry gating for the identification and enumeration of CD19⁺B-cells.

- 946 947
- 948

949 Extended Data Table 1: PhIP-Seq Cohort Demographics

	Healthy	Longitudinal	IVIG	Rituximab	CD19 CAR-T	BCMA CAR-T
Number	79	7	4	7	14	9
Male sex (%)	41 (51.9)	2 (28.6)	1 (25)	2 (28.6)	9(64.3)	4 (44.4)
Median age in years (IQR)	48 (36- 55.5)	74 (71.5- 76.5)	Ranges*	Ranges**	58 (47-64)	65 (60-70)
Race and Ethnicity (%)						
White	63 (77.7)	7 (100)	3 (75)	6 (85.7)	14 (100)	8 (88.9)
Black	1 (1.2)	0	0	1 (14.3)	0	0
Hispanic/Latinx	10 (12.3)	0	0	0	0	0
Asian/Pacific Islander	3 (3.7)	0	1 (25)	0	0	0
Multiple Races	3 (3.7)	0	0	0	0	0
Unknown/Other	1 (1.2)	0	0	0	0	1 (11.1)

950 * Age ranges at time of first sample collection: 26-30 years, n=1; 31-35 years, n=1; 35-40 years,

951 n=1; 51-55 years, n=1.

952 **Age ranges at time of first sample collection: <20 year old, n=1; 21-25 years, n=1; 35-40

953 years, n=1; 61-65 years, n=2, 66-70 years, n=2.

954

955 Extended Data Table 2: Healthy Longitudinal Patient Clinical Details

ID	Duration	Autoimmunity	Cancer	Immunomodulation
Patient 1	63 months	None	None	None

It is made available under a CC-BY-NC 4.0 International license .

Patient 2	25 months	None	Basal cell carcinoma	None
Patient 3	75 months	None	None	None
Patient 4	92 months	None	None	None
Patient 5	61 months	Sjögren's Disease	None	None
Patient 6	50 months	None	None	None
Patient 7	77 months	None	None	None

956 957

Extended Data Table 3: IVIG Sample Details

ID	Sample Timing	Immunomodulation	Last IVIG Dose
Patient 1			
	Initial	None	Naïve
	6 weeks later	Prednisone/Imuran	3 weeks prior
Patient 2			
	Initial	None	Naïve
	14 weeks later	Prednisone	1 day prior
Patient 3			
	Initial	Prednisone	Naïve
	7 weeks later	Prednisone	2 days prior
Patient 4			
	Initial	None	Naïve
	21 weeks later	Prednisone	5 weeks prior

958 959

Extended Data Table 4: Rituximab Sample Details

ID	Autoantibody	Sample	Immunomodulation	Rituximab
Patient 1	AchR			
		1	Prednisone	Naïve
		2	Prednisone	1.1
		3	Prednisone	3.9
		4	Prednisone	3.4
		5	Prednisone	6.1
		6	Prednisone	24.6
Patient 2	MuSK			
		1	Prednisone	Naïve
		2	Prednisone	2.3
		3	Prednisone	5.1
		4	Prednisone	4.8
Patient 3	MuSK			
		1	Prednisone	6.1
		2	Prednisone	5.1

It is made available under a CC-BY-NC 4.0 International license .

		3	None	68.9
Patient 4	MuSK			
		1	None	8
		2	None	7.9
		3	None	24.7
Patient 5	MuSK			
		1	None	17.8
		2	None	1.3
		3	None	8.6
		4	None	13.9
		5	None	18.8
		6	None	21
		7	None	5.7
		8	None	1.6
Patient 6	MuSK			
		1	Prednisone	Naïve
		2	Prednisone, Imuran	1.7
		3	Prednisone, Imuran	4.6
		4	Prednisone, Imuran	4.7
		5	Prednisone, Imuran	8.5
Patient 7	AChR			
		1	Prednisone, Imuran	5.7
		2	Prednisone, Imuran	7
		3	None	24.1

960

961 962

Extended Data Table 5. CAR-T Sample Details

CAR-T	Patient	Malignancy	Post-CAR-T Sample Timing (weeks)	Prior therapy (months pre-CAR- T)	Concurrent treatment (days prior to second sample)
BCMA					
	Patient 1	MM	51	IVIG, 6	IVIG, 117
	Patient 2	MM	27	IVIG, 4	IVIG, 56
	Patient 3	MM	30	None	None
	Patient 4	MM	61	None	IVIG, 68
	Patient 5	MM	29	BCMA, 3	IVIG, 112
	Patient 6	MM	29	Daratumumab, 3	IVIG, 117
	Patient 7	MM	30	Daratumumab, 5	IVIG, 47
	Patient 8	MM	22	None	None

It is made available under a CC-BY-NC 4.0 International license .

	Patient 9	MM	22	None	None
CD19					
	Patient 1	Lymphoma	33	Polatuzumab, 1	None
	Patient 2	Lymphoma	28	Autologous HCT, 7	None
	Patient 3	Lymphoma	32	None	None
	Patient 4	Lymphoma	36	None	None
	Patient 5	Lymphoma	27	Ibrutinib, 1	IVIG, 121
	Patient 6	Lymphoma	30	None	None
	Patient 7	Lymphoma	29	None	IVIG, 59
	Patient 8	Lymphoma	26	None	None
	Patient 9	Lymphoma	30	None	IVIG, 28
	Patient 10	Lymphoma	35	Autologous HCT, 8	None
	Patient 11	Lymphoma	30	None	IVIG, 28
	Patient 12	Lymphoma	21	None	None
	Patient 13	Lymphoma	27	None	None
	Patient 14	Lymphoma	27	None	IVIG, 155

963

964 **Table Legend:** MM=multiple myeloma; Sample timing refers to number of weeks between

965 CAR-T infusion and the post-infusion sample being drawn; Prior therapy lists additional

966 immunomodulatory therapies given in the year prior to initial sample collection, and the number

967 of months between administration of the therapy and collection of the initial sample, excluding

968 the pre-CAR-T conditioning chemotherapy which consists of cyclophosphamide and fludarabine

969 for every patient; Concurrent treatment lists the number of days prior to the second sample being

970 collected when treatment was administered, only IVIG is listed because no other B cell or

- 971 antibody modulating therapies were given.
- 972

973 Extended Data Table 6: Multiplex Bead-based Protein Array Antigen Panel

Antigen	Antigen Vendor	Antigen Catalog #
IL-1A	Peprotech	200-01A
IL-2	Peprotech	200-02
IL-4	Peprotech	200-04
IL-6	Peprotech	200-06
IL-7	Prospec	CYT-214
IL-11	Peprotech	200-11
IL-15	Peprotech	200-15
IL-17A	Peprotech	200-17
IL-17F	Peprotech	200-25
IL-21	Peprotech	200-21
IL-22	Peprotech	200-22
IL-23	Peprotech	200-23
IL-31	Peprotech	200-31

Influenza A HA (H1)	Kim Lab - Stanford	N/A	
Haemophilus Influenzae B	Creative Diagnostics	DAGHIB002	
Influenza A HA (H3)	Kim Lab - Stanford	N/A	
RSV-F Protein	Sino	11049-V08B	
EBV p18	Prospec	EBV-273	
EBV EA-D	MyBioSource	MBS319448	
HAV VP1	Creative Diagnostics	DAG2415	
EBV EBNA-1	Abcam	ab138345	
EBV EA	Prospec	EBV-272	
HBsAg	MyBioSource	MBS142509	
Varicella Zoster Glycoprotein E	MyBioSource	MBS553197	
EV71 VP1 Capsid Protein	BioMART	Custom Request	
Mumps Nucleoprotein	Prospec	MMP-001	
Rubella E1	Prospec	RUB-291	
Measles Nucleoprotein	MyBioSource	MBS319759	
AcmNPV gp64	Sino Biological	40496-V08B	
Rhinovirus VP1	MyBioSource	MBS1220686	
Parainfluenza Hemagglutinin- neuraminidase	Sino Biological	40629-V07B	
HSV glycoprotein G	MyBioSource	MBS145445	
CMV gB	Prospec	CMV-211	
HMPV Glycoprotein G	Sino Biological	40791-V08H	
Anti-Human IgG Fc fragment Spesific	Jackson	109-005-008	
Anti-Human IgG F(ab') fragment specific	Jackson	109-005-006	
Anti-Human IgG (H+L)	Jackson	109-005-003	
Human IgG from serum	Sigma	I4506	
PDC-E2	Diarect	A17901	
ТРО	Diarect	A12101	
TG	Diarect	A12201	
CXCL10	Peprotech	300-12	
CXCL9	Peprotech	300-26	

It is made available under a CC-BY-NC 4.0 International license .

MIP-1alpha (CCL3)	Peprotech	300-08	
CXCL13	Peprotech	300-47	
CXCL16	Peprotech	300-55	
CXCL5	Peprotech	300-22	
CCL21	Peprotech	300-35A	
CXCL8	Peprotech	200-08	
CCL22	Peprotech	300-36	
CCL19	Peprotech	300-29B	
CCL25	Peprotech	300-45	
CXCL17	Prospec	CHM-024	
IFN-alpha1	Prospec	CYT-291	
IFN-alpha2	R&D	11101-2	
IFN-alpha6	Origene	TP760329	
IFN-alpha7	Prospec	CYT-196	
IFN-alpha8	Sino	10347-H08H	
IFN-alpha10	Sino	10349-H08H	
IFN-beta	Peprotech	300-02BC	
IFN-epsilon	R&D	9667-ME-025/CF	
IFN-omega	Peprotech	300-02J	
IFN-gamma	Peprotech	300-02	
IFN-lambda1	Peprotech	300-02L	
IFN-lambda2	Peprotech	300-02K	
C3	Complement Tech	A113	
Clq	EMD	204876	
FGF7	Peprotech	100-19	
GM-CSF	Peprotech	300-03	
LIF	Peprotech	300-05	
PDGFBB	Peprotech	100-14B	
VEGFB	Peprotech	100-20B	
TNF-alpha	Peprotech	300-01A	
IL1RA	Peprotech	200-01RA	
ACE2	Sino biological	10108-H05H	
Proteinase 3	Diarect	A18601	
BPI	Sigma	SRP6307	
IFN-lambda3	R&D	5259-IL-025/CF	
IL-33	Peprotech	200-33	
CCL26	Peprotech	300-48	

974

975 Extended Data Table 7: Additional BCMA Patient Demographics

It is made available under a CC-BY-NC 4.0 International license .

Patient	Cohort	Age Range (years)	Sex	Race/Ethnicity
Patient 10	BCMA	51-55	Female	White
Patient 11	BCMA	61-65	Male	White
Patient 12	BCMA	51-55	Male	Not reported
Patient 13	BCMA	56-60	Male	White

976

977 Extended Data Table 8: Additional BCMA Sample Details

CAR-T	Patient	Malignancy	Post-CAR-T Sample Timing (weeks)	Prior therapy (months pre- CAR-T)	Concurrent treatment (days prior to second sample)
BCMA					
	Patient 10	MM	27	None	None
	Patient 11	MM	24	None	None
	Patient 12	MM	27	None	None
	Patient 13	MM	22	Elotuzumab, 4	None

978

979 **Table Legend:** MM=multiple myeloma; Sample timing refers to number of weeks between

980 CAR-T infusion and the post-infusion sample being drawn; Prior therapy lists additional

981 immunomodulatory therapies given in the year prior to initial sample collection, and the number

982 of months between administration of the therapy and collection of the initial sample, excluding

983 the pre-CAR-T conditioning chemotherapy which consists of cyclophosphamide and fludarabine

984 for every patient.

985